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Summary
Natural killer (NK) cells exhibit dysregulated effector function in adult
chronic hepatitis B virus (HBV) infection (CHB), which may contribute to
virus persistence. The role of NK cells in children infected perinatally with
HBV is less studied. Access to a unique cohort enabled the cross-sectional
evaluation of NK cell frequency, phenotype and function in HBV-infected
children relative to uninfected children.We observed a selective defect in NK
cell interferon (IFN)-γ production, with conserved cytolytic function, mir-
roring the functional dichotomy observed in adult infection. Reduced
expression of NKp30 on NK cells suggests a role of impaired NK-dendritic
cell (DC) cellular interactions as a potential mechanism leading to reduced
IFN-γ production. The finding that NK cells are already defective in paediat-
ric CHB, albeit less extensively than in adult CHB, has potential implications
for the timing of anti-viral therapy aiming to restore immune control.
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Introduction
Perinatal transmission of hepatitis B virus (HBV) is the
most common mode of transmission world-wide. Despite
the availability of an effective prophylactic vaccine, HBV
infection during infancy or early childhood is common in
areas of high endemicity. In these regions, mother-to-infant
transmission accounts for approximately 50% of chronic
infections. The age at infection primarily determines the
rate of progression from acute to chronic infection, which is
approximately 90% in the perinatal period, 20–50% in chil-
dren aged 1–5 years and less than 5% in adults [1] [2–4].
Although the majority of children with chronic hepatitis B
infection (CHB) are asymptomatic, they are at increased
risk of developing progressive liver disease and complica-
tions such as hepatocellular carcinoma (HCC) before the
third decade of life [5,6].
Perinatally infected children are considered predomi-
nantly to be in the immunotolerant phase, with a high viral
load, detectable HBeAg and, initially, minimal detectable
liver inflammation [4]. However, our knowledge of the
natural history of paediatric HBV infection is severely
limited by the difficulty in sampling this group and age-
matched controls. This has led to the widely held view that
immunotolerant children are unlikely to respond to anti-
viral therapy. Recent work in young adults in the
immunotolerant phase of CHB challenge the dogma that
younger patients lack an HBV-specific adaptive immune
response, suggesting that they may be more suitable treat-
ment candidates than considered previously [7–9]. Thus, a
more comprehensive understanding of the various immu-
nological parameters during paediatric HBV infection may
inform clinical management more clearly. In this study we
have focused on natural killer (NK) cells, a critical compo-
nent of anti-viral defence, enriched in the liver and shown
to be dysregulated in adult CHB.
NK cells display a multitude of anti-viral effector func-
tions through the production of cytokines and direct target
cell recognition and lysis [10]. The intensity and quality of
NK cell cytotoxic and cytokine responses is regulated by a
wide array of NK cells receptors that are finely tuned to
ensure self-tolerance while permitting effective responses
against invading pathogens [10,11]. NK cell function may
be calibrated further by the local cytokine microen-
vironment and bi-directional interactions between innate
and adaptive immune cells [12]. Besides their direct anti-
viral function, it is recognized increasingly that NK cells
also have an important immunoregulatory role [13–16].
Reports on the role of NK cells in HBV infection have
focused on adult life, when chronic infection has usually
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already been long-established. We, and others, have
previously demonstrated a functional dichotomy, with
conserved NK cytolytic function and impaired IFN-γ, in
adult patients with CHB [17–19]. More recently we have
shown that NK cell activity can regulate the adaptive
immune response, as well as the degree of immunopathol-
ogy, in CHB [16,20]. Moreover, treatment with pegylated
(Peg)-interferon (IFN)-α mediated functional augmenta-
tion of NK cell effector function, which correlated with
peak virological responses, highlighting the anti-viral
potential of NK cells [21]. Little is known, however,
about NK cell function in children with CHB. Previous
studies have shown that neonatal NK cells have an
immature phenotype that may compromise their
capacity to respond to viral infections [22–25]. It remains
unknown how NK cell populations and functions are
modified during the course of CHB from childhood to
adulthood. Here we used multi-parametric flow cytometry
to investigate whether the frequency, phenotype and
function of NK cells is altered in a cohort of perinatally
HBV-infected children and compared them to uninfected
children.
Materials and methods
Study population
Eighteen children with CHB were included into the study.
The patients were recruited from the Department of Pae-
diatrics, Hvidovre Hospital, University of Copenhagen,
Denmark. All patients were negative for HIV, hepatitis A,
hepatitis C and hepatitis D virus and were considered
healthy apart from their CHB. None of the children had
received anti-viral treatment for HBV. Blood samples were
obtained at the children’s routine clinical visits during the
period October 2008–August 2011. Sixteen healthy,
HBsAg-negative children were included as controls during
the period August 2010–August 2011. Patient characteris-
tics and classification are summarized in Table 1. The
study protocol was approved by the Ethical Committee
Capital Region of Denmark, reference number H-KF-
255584, and parents of all participants gave written
informed consent.
Isolation and storage of peripheral blood mononuclear
cells (PBMCs) and plasma
Blood was obtained in 8-ml BD Vacutainer™ CPT ™ tubes
with sodium heparin, and peripheral blood mononuclear
cells (PBMCs) were isolated according to the manufactur-
er’s instructions. Freezing medium [10% dimethyl-
sulphoxide (DMSO) and 90% fetal calf serum (FCS)] was
added, and the cells were stored at −135°C. Plasma was col-
lected and frozen at −80°C. Ta
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Extracellular staining and flow cytometric analysis
For phenotypical analysis, PBMCs isolated from children
with CHB and uninfected controls were stained with
fluorochrome-conjugated antibodies to CD3-phycoerythrin
(PE)-cyanin 7 (Cy7), NK group 2D (NKG2D)-PE
(eBioscience, Hatfield, UK), CD56-energy-coupled dye
(ECD) (Beckman Coulter, High Wycombe, UK), tumour
necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL)-PE, CD16-allophycocyanin (APC)-Cy7, CD94-
fluorescein isothiocyanate (FITC), human leucocyte antigen
D-related (HLA-DR)-V500, NKp46-V450 (BD Biosciences,
Oxford, UK), NKG2A-Alexa700, NKG2C-PerCP (R&D
Systems, Abingdon, UK) and NKp30-APC (Miltenyi Biotec,
Surrey, UK) or isotype-matched controls, in the presence of
fixable live/dead stain (Invitrogen, Paisley, Scotland, UK).
Cells were acquired on a fluorescence activated cell sorter
(FACS) LSRII multi-colour flow cytometer and analysed
using FlowJo analysis software (Tree Star, Ashland, OR,
USA).
Cytokine production
For intracellular staining for IFN-γ production, PBMCs
were incubated with 50 ng/ml of rhIL-12 (Miltenyi Biotec)
and 50 ng/ml of rh-IL18 (R&D Systems) for 21 h at 37°C.
One mM monensin (Sigma-Aldrich, Gillingham, UK)
was added for the final 3 h. Cells were stained with antibod-
ies to CD3-PE-Cy7 (eBioscience), CD16-APC-Cy7 (BD
Biosciences) and CD56-ECD (Beckman Coulter) and sub-
sequently fixed and permeabilized, followed by intracellular
staining for IFN-γ-V450 (BD Biosciences). Dead cells were
excluded by live/dead stain (Invitrogen).
For TNF-α production, PBMCs were stimulated with
phorbol myristate acetate (PMA) (3 ng/ml) and ionomycin
(100 ng/ml) (Sigma-Aldrich) for 3 h in the presence of
1 mM of monensin (Sigma-Aldrich). Cells were stained
with antibodies to CD3-PE-Cy7 (eBioscience), CD16-APC-
Cy7 (BD Biosciences) and CD56-ECD (Beckman Coulter)
in the presence of live/dead stain followed by fixing,
permeabilization and intracellular staining for TNF-α-FITC
(BD Biosciences).
CD107 degranulation assay
NK cell degranulation was measured as described previ-
ously [26]. Briefly, PBMCs were incubated with K562 cells
[5:1 effector : target (E : T) ratio] for 3 h at 37°C following
overnight stimulation with a combination of 50 ng/ml
recombinant human (rh)IL-12 and rhIL-18 (Miltenyi
Biotec, R&D Systems). CD107a-PE antibody (BD
Biosciences) was added at the time of stimulation with
target cells along with 1 mM monensin prior to staining
and acquisition.
Plasma concentration of cytokines and chemokines
determined by cytometric bead array (CBA)
CBA 11 plex RTU FlowCytomix Kit (eBioscience) was used
for the determination of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8,
IL-10, IL-12p70, IFN-α, IFN-γ, TNF-α, TNF-β, chemokine
(C-C motif) ligand 3 (CCL3), chemokine (C-X-C motif)
ligand 9 (CXCL9) and chemokine (C-X-C motif) ligand 10
(CXCL10) in plasma samples, according to the manufactur-
ers’ protocols.
Statistical analysis
Statistical analysis was performed between HBV patients
and healthy controls using the Mann–Whitney U-test. Cor-
relations between variables were evaluated with the Spear-
man’s rank correlation test (Prism version 4; GraphPad
Software Inc., San Diego, CA, USA). P < 0·05 was consid-
ered to be significant for all tests.
Results
Comparable NK cell frequency and subsets in CHB and
healthy children
NK cell populations exhibit dynamic changes during the
first years of life and become more comparable with adult
NK cells after the age of 5 years [27]. To assess the impact of
HBV infection on NK cell frequency and subset distribution
we compared the frequency and distribution of different
NK cell subpopulations (CD56bright and CD56dim) in the
peripheral blood of 18 children with CHB and 16 healthy
children (Table 1). We found no significant difference in the
proportions of total circulating NK cells (CD56+CD3−) or
CD56bright CD16−/dim, CD56dim CD16+ and CD56–CD16+ NK
cell subsets between the two groups (Fig. 1a,b). To evaluate
whether there were any perturbations in the proportions of
NK cell subsets according to disease activity, results were
analysed according to HBeAg status, viral load and levels of
alanine transaminase (ALT). Our data demonstrate that
there was no skewing of frequencies within the NK cell
peripheral compartment during paediatric HBV infection,
irrespective of disease status (data not shown). Similarly, we
did not detect any significant differences in frequencies of
CD56+CD3+ T cells, previously noted to be increased in
cytomegalovirus (CMV)-seropositive individuals [28],
between the two groups [mean ± standard error of the
mean (s.e.m.), 2·291 ± 0·4768 versus 2·209 ± 0·5741,
P = 0·8968, data not shown].
The expression of HLA-DR on NK cells has been used
previously as a marker of cellular activation [29]. We there-
fore analysed the levels of the activation marker HLA-DR
on peripheral NK cells and subsets in CHB children and
healthy controls. Expression of HLA-DR on NK cells was
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not found to be statistically different between CHB children
and healthy controls (Fig. 1c).
Impaired IFN-γ production but intact cytolytic
function by NK cells in paediatric HBV patients
Given that NK cells have comparable subset distribution
and levels of activation between the two groups, we next
assessed the effector function of these cells.
NK cells are a potent source of cytokines such as IFN-γ
that, in addition to its potential proinflammatory effects,
can mediate important direct non-cytolytic anti-viral
effects on HBV [30,31]. Stimulation of PBMCs from chil-
dren with CHB with a combination of IL-12/18 showed a
1·5-fold reduction in IFN-γ-producing NK cells compared
to healthy controls [Fig. 2a(i,ii)]. Although the CD56bright
subset was thought originally to be the main cytokine-
producing subset, it is now recognized that the CD56dim
subset makes a significant contribution to IFN-γ secretion
[32]. Our results indicated reduced IFN-γ in total NK cells
derived from the CD56dim subset, whereas production of
IFN-γ was maintained from the CD56bright subset
[Fig. 2a(ii)]. The reduced capacity of NK cells to produce
IFN-γ was most notable in patients with liver inflammation
and/or high viral load (active, and immunotolerant versus
inactive phases, as defined in Table 1) [Fig. 2b(i)]. Interest-
ingly, not all immunotolerant patients were deficient in
their ability to produce IFN-γ [Fig. 2b(ii)].
Intracellular TNF-α was not detected after overnight
stimulation with IL-12/IL-18 (own observations and
reported previously). The ability of NK cells to produce
TNF-α was assessed following stimulation with PMA/I,
with no significant difference between children with CHB
and healthy children (Supporting information, Fig. S1a).
PMA/I stimulated cells from patients resulted in similar
levels of IFN-γ production compared to healthy
controls, suggesting that NK cells retain their ability to
respond to this strong stimulus (Supporting information,
Fig. S1b).
In addition to their non-cytolytic ability, NK cells typi-
cally kill target cells through cytolytic pathways, including
the TRAIL pathway. We have previously found TRAIL to be
up-regulated on NK cells during episodes of HBV-related
liver inflammation [19,20], contributing to hepatocyte
apoptosis during HBV-related liver flares [20], and also lim-
iting HBV-specific T cell responses [16]. We therefore
screened NK cells for changes in TRAIL expression between
CHB and healthy children, and determined their
degranulation potential upon co-culture with K562 target
cells [major histocompatibility complex (MHC) devoid].
Neither the inducible expression of CD107a nor the ex-vivo
expression level of TRAIL differed between the groups,
demonstrating intact NK cell cytolytic function
[Fig. 2c(i)(ii),d(i)(ii)].
Reduced frequency of NK cells expressing activating
natural cytotoxicity receptors in CHB children
To investigate whether the impaired ability of NK cells to
produce IFN-γ is paralleled by an altered phenotypical
NK cell profile in children with CHB, we performed
multi-colour flow cytometry for a panel of activating and
inhibitory NK cell receptors. Variation of the NK cell
phenotype has been reported with age, highlighting a
continuum of changes during immunological ageing
[23,24,33].
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The C-lectin family of receptors are expressed on the
surface of NK cells as heterodimers with CD94. They
include the CD94/NKG2C activating complex and the
inhibitory CD94/NKG2A receptor. Altered expression of
these receptors has been described in adult CHB [18,34].
However, we found that the frequencies of NK cells express-
ing the inhibitory receptor NKG2A and the activating
receptor NKG2C and co-receptor CD94 were not different
between the two groups of children (Fig. 3a, summary
data). The levels expressed as mean fluorescent intensity
(MFI) were also similar in CHB children and healthy con-
trols (data not shown). Subanalysis of human CD56+CD3–
NK cell subsets by CD94 surface expression did not reveal
any differences between healthy controls and CHB children
(data not shown). CMV infection selectively shapes NK cell
receptor repertoire in healthy individuals, inducing the
expression of NKG2C [35]; this phenotypical feature is par-
ticularly pronounced in individuals with viral excretion
[36]. CMV-associated expansion of NKG2C+ NK cells has
also been reported in adult patients with chronic HBV and
hepatitis C virus (HCV) infection [37]; however, the levels
of expression were highly heterogeneous. In our study, data
on CMV seropositivity were not available for healthy chil-
dren, whereas CHB children were all CMV-seropositive
with the exception of one patient, precluding a more
detailed analysis of any imprint of CMV on NK cells from
infected versus healthy children. Interestingly, CMV serop-
ositivity in the study group did not affect NK cell expression
of NKG2C or NKG2A. Expression of the activating receptor
NKG2D was also found to be similar within the two groups
(Fig. 3a).
To further exclude any potential bias conferred by
CMV seropositivity on the NK cell repertoire, we analysed
the expression of CD57, an important marker of NK cell
terminal differentiation and CMV status [38]. We detected
no significant differences in the expression of CD57
between healthy controls and HBV-infected children
(Fig. 3a).
The natural cytotoxicity receptors (NCRs) are a family of
activating receptors that are expressed almost exclusively by
NK cells and include NKp30, NKp46 and NKp44 [39].
Analysis of the NCRs demonstrated a trend towards a
decreased frequency of NKp46 expressed by NK cells in
children with CHB (Fig. 3b), but this did not reach statisti-
cal significance. However, expression of NKp30 was reduced
on total NK cells of children with CHB [Fig. 3c]. Notably
only the CD56dim subset showed significantly decreased
expression of NKp30 [Fig. 3c], in line with the restriction
of functional defects to this subset. The reduction in the
levels of NKp30 expression was more pronounced in chil-
dren with active disease [Fig. 3d] and varied within
immunotolerant patients [Fig. 3d]. Evaluation of NKp30
on total NK cells by MFI also revealed significantly
lower values in CHB children (mean ± s.e.m., healthy
640·3 ± 76·27 versus CHB 428 ± 90·39 P = 0·0218, data not
shown). We did not detect any gender-related differences in
NKp30+NK cells within and between healthy and CHB
children.
The levels of IL-10 are not increased in children
with CHB
The intensity and quality of NK cell cytotoxic and
cytokine responses depends further on the cytokine
microenvironment. We have demonstrated previously that
IL-10 restrains NK cell IFN-γ production in adult patients
with CHB, with levels of IL-10 increased significantly in
adults with CHB compared to healthy controls [19,40]. We
therefore examined the cytokine profile in plasma samples
from our cohort of CHB children and healthy controls
(Table 2). No significant differences were detected in the
circulating levels of the panel of 14 plasma cytokines/
chemokines examined. In particular, unlike in adults with
CHB, the impaired capacity of NK cells to produce IFN-γ
was not associated with an increase in circulating IL-10 in
paediatric CHB (Table 2).
Discussion
Innate immunity is thought be a major contributor to viral
elimination during the early years of life before the adaptive
immune system matures [25,41]. Accumulating evidence
supports a role for NK cells in the immunopathogenesis of
CHB in adults [42]. In particular, recent data from adults
with CHB have highlighted that NK cells are capable of
mediating both anti-viral and immunoregulatory functions,
while also contributing to hepatocyte turnover and immun-
opathology via death receptor pathways [16,20,43].
However, our knowledge of NK cell function in paediatric
populations is limited. Human immunodeficiency virus
(HIV) infection is known to alter the phenotype and func-
tion of NK cells in children [44]. Here we studied the
impact of paediatric HBV infection on NK cell phenotype
and function in relation to clinical status. Our results indi-
cate that NK cell effector capacity is compromised in HBV-
infected children relative to their uninfected counterparts,
demonstrating early defects in anti-viral function.
IFN-γ is one of the most prominent cytokines released by
NK cells and a potent non-cytolytic mechanism of viral
clearance from the HBV-infected liver [45]. Our analysis of
NK cell effector potential in our paediatric cohort of
patients with CHB revealed preservation of cytolytic func-
tion and a decrease in IFN-γ production compared to
healthy children. The observed defect was more marked in
children with active disease. Our results demonstrated that
even some children classified as ‘immunotolerant’ retain the
ability to respond to cytokine stimuli and produce equiva-
lent levels of cytokines compared to healthy controls,
arguing against a state of complete immunological toler-
ance. The overall NK cell IFN-γ dysfunction was not as
I. L. Heiberg et al.
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extensive as in the adult population with CHB, only affect-
ing the CD56dim subset. By contrast, we found significant
reductions in IFN-γ-producing capacity by both CD56dim
and CD56bright NK cells in adults with CHB [19], suggesting
that cumulative exposure to HBV has a more profound and
progressive effect on NK cell anti-viral potential. Thus a
pathway specific to cytokine production by CD56dim NK
cells is dysregulated in children, similar to adult patients
with CHB. However, HBV-infected children retain their
ability to respond to stimulation with PMA/I, whereas this
effect is lost in the adult population [19]. These findings
suggest sustained exposure to HBV infection is progres-
sively detrimental to NK cell subset function, reminiscent of
the hierarchical loss of effector function exhibited by
exhausted T cells. Potent anti-viral therapy in CHB adults
partially restores the ability of NK cells to produce IFN-γ
from the CD56dim subset and improves their de-novo activa-
tion [18,19]; our data raise the possibility that these defects
may be more effectively reversed in paediatric patients by
earlier anti-viral treatment.
The observed differences in NK cell function could not
be attributed to changes in the proportions of NK cells or
subsets. We therefore postulated that NK cells with unique
receptor profiles may predominate in paediatric CHB that
may partly explain their differences in effector function.
The activating NCR NKp30 was significantly down-
regulated in CHB children. Importantly, we found that this
phenotypical alteration was more prominent in children
with active disease and in the CD56dim NK cell subset, analo-
gous to the functional defect, and was not influenced by dis-
crepancies in age and gender within/between the two
groups. NKp30 plays an important role in NK–dendritic
cell (DC) cross-talk [46] and has also been reported to be
down-regulated significantly in adult CHB [18], which may
compromise NK–DC interactions. In addition to its ability
to induce cytotoxicity, engagement of NKp30 can mediate
the production of cytokines such as IFN-γ. In HIV infec-
tion, defective interaction with mDC through impaired
function of NK cell NKp30 leads to their impaired secretion
of IFN-γ by NK cells [47]. In adult CHB, mDC are mark-
edly impaired in their ability to activate NK cells, which
leads in turn to diminished NK cell IFN-γ production
without affecting cytotoxicity [48]. Of relevance, the immu-
noregulatory effects of HBsAg, HBV (whole virion) and
HBeAg may impair DC function and thereby further impair
NK cell function [49]. This may, in turn, influence T cell
differentiation and shaping of adaptive immune responses.
Equally, defective cross-talk and editing of DCs by NKs
could affect the development of adaptive T cell anti-viral
immunity through restricting antigen presentation [50,51].
Although our findings suggest a role for accessory cells, the
contribution of NKp30–NK cell reciprocal interaction with
DC in paediatric HBV infection remains to be established.
Alternatively, NK cells expressing NKp30 may be recruited
preferentially to the liver, the site of HBV replication. Levels
of NKp46, despite a trend towards lower expression, were
not reduced significantly in children with HBV. This may be
important for the maintenance of cytotoxicity. Study of a
larger cohort of patients and matched controls could help
dissect out the effect of race- and gender-related variations
in the expression of NKp46, in line with recent published
associations in the context of hepatitis C virus (HCV) [52].
Although we did not analyse the expression of killer cell
immunoglobulin-like receptors (KIR) due to limited
samples, it is well known that different KIR–HLA combina-
tions can modulate NK cell function and influence the
outcome of infectious diseases with HIV and HCV infec-
tions [53,54]. Further work is required to explore how the
KIR repertoire is shaped during the course of CHB and how
perinatal infection with HBV influences NK cell licensing.
The added effect of CMV and other viral pathogens such as
Epstein–Barr Virus (EBV) on shaping of NK cell receptors
and maturational status requires further evaluation in a
larger cohort of patients and healthy donors of similar eth-
nicity. As age and time of infection with additional patho-
gens may be both relevant and inter-related, a prospective
longitudinal assessment would be desirable to remove any
potential confounding factors on the analysis of the impact
of HBV infection. However, the lack of expansion of NK
cells expressing NKG2C and CD57 in our cohort of HBV-
infected children argues against CMV impacting upon the
observed NK cell phenotypical and functional differences in
this study.
The cytokine environment can further shape the effector
functions of NK cells. In adult CHB elevated levels of IL-10,
especially in patients with active disease, selectively modu-
lated NK cell anti-viral function [19]. In this study we did
Table 2. Mean value of cytokine concentration ± standard error of the
mean in children with chronic hepatitis B (CHB) and healthy controls.
CHB patients
(n = 18)
Healthy controls
(n = 16) P-value
IFN-γ 162 ± 87 170 ± 103 0·98
IFN-α 86 ± 42 57 ± 30 0·56
TNF-α 315 ± 312 1003 ± 685 0·83
TNF-β 1424 ± 574 1391 ± 873 0·75
IL-10 13 ± 5 6 ± 3 0·56
IL-12 195 ± 148 15 ± 11 0·57
IL-8 4620 ± 1842 3349 ± 1936 0·75
IL-6 8 ± 2 6 ± 2 0·55
IL-4 0 373 ± 364 0·13
IL-5 1063 ± 1063 2167 ± 1665 0·51
IL-2 112 ± 52 59 ± 34 0·62
IL-1β 347 ± 201 919 ± 644 0·73
CCL3 448 ± 272 736 ± 414 0·74
CXCL9 54 ± 14 223 ± 123 0·42
CXCL10 138 ± 39 84 ± 21 0·34
IFN = interferon; TNF = tumour necrosis factor; IL = interleukin;
CCL = C-C chemokine ligand; CXCL = chemokine (C-X-C motif)
ligand.
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not detect high levels of IL-10 in CHB children compared to
controls. However, it should be noted that only a small
number of children had evidence of liver inflammation. No
alterations in the cytokine milieu were detected to account
for the observed deficiency in NK cell IFN-γ production in
the cross-sectional comparison. Future longitudinal studies
could assess the potential impact of disease fluctuations on
cytokine composition and NK cell homeostasis, phenotype
and effector function.
In summary, we have characterized for the first time a
functional defect in NK cell IFN-γ production in paediatric
CHB. This defect was more prominent in the group of chil-
dren with active disease. The progressive decline in IFN-γ
production by NK cells seen in adults could represent the
cumulative effect of HBV infection on NK cell anti-viral
function. Reduced expression of the NCR NKp30 on NK
cells could account partially for this deficiency via impaired
NK–DC reciprocal interactions. Implementation of univer-
sal vaccination against HBV in newborns has already
reduced the incidence of HBV-related HCC in countries
such as Taiwan [55]. For those chronically infected, a
remaining challenge is the development of a treatment
strategy able to induce HBV immune control, especially in
immunotolerant children [9]. Thus a more comprehensive
understanding of the immune responses during childhood
is highly desirable. In adult CHB, anti-viral treatment can
partially restore NK cell defects in IFN-γ production. Our
data have important implications for the clinical manage-
ment of paediatric HBV patients. Taken together with
recent findings on T cell responses [8], they support consid-
eration of earlier initiation of treatment to include young
patients in the immunotolerant phase, in agreement with
recent studies highlighting their favourable response to
treatment [56,57].
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Fig. S1. Summary bar charts of natural killer (NK) cell
tumour necrosis factor (TNF)-α production (a) and NK
cell interferon (IFN)-γ production (b) after phorbol
myristate acetate (PMA)/I stimulation in healthy children
(n = 13) and children with chronic hepatitis B virus (CHB)
(n = 14). Bars represent the mean ± standard error of the
mean. Statistical analysis was performed using the Mann–
Whitney U-test.
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